Skip to search formSkip to main contentSkip to account menu

IMMU-106

Known as: monoclonal antibody IMMU-106 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits… 
Review
2012
Review
2012
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… 
Review
2009
Review
2009
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell hyperactivity and defective T-cell function… 
2007
2007
8032 Background: An open-label, multicenter study has shown that the humanized anti-CD20 antibody, IMMU-106 (hA20), which has… 
2007
2007
Purpose:Bispecific antibody (bsMAb) pretargeting procedures use divalent hapten-peptides to stabilize the binding of the hapten… 
2006
2006
7530 Background: The humanized anti-CD20 antibody, IMMU-106 (hA20), has similar murine CDRs to rituximab, but the remaining… 
2006
2006
Background: An open-label, multicenter, dose-escalation study in patients with recurrent NHL was initially undertaken to… 
2006
2006
2536 Background: Anti-CD20 and anti-CD22 monoclonal antibodies (MAbs) have been shown to have antitumor activity in non-Hodgkin's… 
2005
2005
Background. Infusion reactions, prolonged infusion times and immunogenicity of the chimeric anti-CD20 antibody, rituximab, may in… 
Highly Cited
2004
Highly Cited
2004
Purpose: A new humanized anti-CD20 monoclonal antibody (MAb), IMMU-106, was evaluated to elucidate its action as an antilymphoma…